biotech · Acute Myeloid Leukemia · Acute Myelogenous Leukemia in Relapse · APTOF
Aptose Biosciences
Aptose Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker APTOF. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Myelogenous Leukemia in Relapse, C
San Diego, USA HQ
2014 Founded
32 Employees
Public company Type
APTOF · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 32
- Programs
- 8
- Drugs
- 1
- Patents
- 7
GTI-2040
Phase 2 · mab · Acute Myeloid Leukemia
GTI-2040 for Acute Myeloid Leukemia is a Phase 2 program (mab) at Aptose Biosciences with 1 ClinicalTrials.gov record(s).
Internal code 2040AML201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aptose Biosciences
- Phase
- Phase 2
- Modality
- mab
- Indication
- Acute Myeloid Leukemia
- Status
- completed
- Trials
- 1